Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
30.90
+0.87 (2.90%)
At close: Mar 20, 2026, 4:00 PM EDT
30.91
+0.01 (0.03%)
After-hours: Mar 20, 2026, 7:43 PM EDT

Celldex Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-258.76-157.86-141.43-112.33-70.51
Depreciation & Amortization
3.383.183.012.93.07
Stock-Based Compensation
36.2234.2423.8915.618.95
Other Adjustments
-5.84-15.73-6.22-6.02-1.37
Change in Receivables
-1.321.93-2.28-0.181.57
Changes in Accounts Payable
11.0311.639.383.123.65
Changes in Other Operating Activities
4.34-35.166.36-6.85-6.28
Operating Cash Flow
-210.95-157.78-107.29-103.73-60.91
Capital Expenditures
-2.71-1.92-1.82-1.83-1.25
Sale of Property, Plant & Equipment
---0.070.03
Purchases of Investments
-384.5-789.92-424.56-188.97-389.88
Proceeds from Sale of Investments
596.29501.71320.6280.67174.95
Investing Cash Flow
209.07-290.13-105.7889.94-216.16
Issuance of Common Stock
2.39441.45218.464.08272.37
Net Common Stock Issued (Repurchased)
2.39441.45218.464.08272.37
Financing Cash Flow
2.39441.45218.464.08272.37
Net Cash Flow
0.52-6.465.39-9.71-4.69
Free Cash Flow
-213.66-159.7-109.11-105.56-62.16
FCF Margin
-13829.06%-2274.89%-1584.97%-4478.57%-1336.44%
Free Cash Flow Per Share
-3.22-2.48-2.25-2.25-1.45
Levered Free Cash Flow
-242.72-180.13-124.5-114.98-71.32
Unlevered Free Cash Flow
-271.33-217.35-137.61-117.89-71.82
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q